Development of clinical methods of iron deprivation for suppression of neoplastic and infectious diseases

Cancer Investigation

Volumn 17, Issue 7, 1999, Pages 507-513

  Weinberg, Eugene D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHELATING AGENT; CYCLOPHOSPHAMIDE; DEFERIPRONE; DEFEROXAMINE; DIETHYLHYDROXYPYRIDINONE; ETOPOSIDE; GALLIUM; HYDROXYCHLOROQUINE; IFOSFAMIDE; N,N' BIS(2 HYDROXY BENZOYL)ETHYLENE DIAMINE N,N' DIACETIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RETINOIC ACID; THIOTEPA; UNCLASSIFIED DRUG; VINBLASTINE;

BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CHELATION; CHRONIC HEPATITIS; DRUG INDUCED DISEASE; HEARING IMPAIRMENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VISUAL IMPAIRMENT;

EID: 0032867670     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032860     Document Type: Review

References (61)

1. Moirand R, Mortaji AM, Loreal O, et al: A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349:95-97, 1997.
2. Kontoghiorghes GJ, Weinberg ED: Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 9:33-45, 1995.
3. Porter JB, Huehns ER, Hider RC: The development of iron chelating drugs. Baillier's Clin Haemalol 2:257-292, 1989.
4. Weinberg ED: The role of iron in cancer. Eur J Cancer Prevent 5:19-36, 1996.
5. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 89:739-761, 1997.
6. Hann H-WL, Stahlhut MW, Rubin R, et al: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70:2051-2056, 1992.
7. Donfrancesco A, Deb G, De Sio L, et al: Role of deferoxamine in tumor therapy. Acta Haematol 95:66-69, 1996.
8. Boelaert JR, de Locht M, Van Cutsem J: Desferrioxamine: its effects on the growth of micro-organisms in vitro and in experimental infections. Rev Med Microbiol 4:171-175, 1993.
9. Hider RC, Liu Z: The treatment of malaria with iron chelators. J Pharm Pharmacol 49 (Suppl 2):59-64, 1997.
10. Weinberg GA: Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 38:997-1003, 1994.
11. Weinberg ED: Iron withholding: a defense against viral infections. BioMetals 9:393-399, 1996.
12. Brittenham GM: Development of iron-chelating agents for clinical use. Blood 80:569-574, 1992.
13. Timeus F, Valle P, Crescenzio N, et al: Effect of desferrioxamine and hydroxypyridones on hemopoietic progenitors and neuroectodermal tumor cells. Am J Hematol 47:183-188, 1994.
14. Richardson DR, Milnes K: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthyl-aldehyde benzoyl hydrazone. Blood 89:3025-3038, 1997.
15. Dabrowiak JC: The coordination chemistry of bleomycin: a review. J Inorg Biochem 13:317-337, 1980.
16. Myers C, Gianni L, Zweier J: Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. Federation Proc 45:2792-2797, 1986.
17. Moore JC, Lai H, Li J-R: Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98:83-87, 1995.
18. Meshnick SR, Taylor TE, Kamchonwomgpaisan S: Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60:301-315, 1996.
19. Byrd TF, Horwitz MA: Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and Interferon gamma-activated human monocytes depending upon its degree of iron saturation. J Clin Invest 88:1103-1112, 1991.
20. Bezault J, Bhimani R, Wiprovnik J: Human lactoferrin inhibits growth of solid tumors and development of metastases in mice. Cancer Res 54:2310-2312, 1994.
21. Dhaenens L, Szczebara F, Husson MO: Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect Immun 65:514-518, 1997.
22. Miehlke S, Reddy R, Osato MS: Direct activity of recombinant human lactoferrin against Helicobacter pylori. J Clin Microbiol 34:2593-2594, 1996.
23. Oguchi S, Walker WA, Sanderson IR: Iron saturation alters the effect of lactoferrin on the proliferation and differentiation of human enterocytes (Caco-2 cells). Biol Neonate 67:330-339, 1995.
24. Brock JH, Djeha A, Ismail M: Cellular responses to iron and iron compounds. In: Progress in Iron Research, edited by C Hershko, New York, Plenum Press, 1994, pp. 91-100.
25. Witte DL, Crosby WH, Edwards CQ, et al: Hereditary hemochromatosis. Clin Chim Acta 245:139-200, 1996.
26. Merk K, Mattson B, Mattson A, et al: The incidence of cancer among blood donors. Int J Epidemiol 19:505-509, 1990.
27. Weinberg RJ, Ell SR, Weinberg ED: Blood-letting, iron homeostasis, and human health. Med Hypoth 21:441-443, 1986.
28. Rush B: A defense of blood letting as a remedy for certain diseases. In: Medical Inquiries & Observations, Vol. IV, Philadelphia, M Carey et al, 1818, pp. 173-224.
29. Israel JL, McGlynn KA, Hann H-WL, Blumberg BS, et al: Iron-related markers in liver cancer. In: Iron in Immunity, Cancer and Inflammation, edited by M deSousa, JH Brock, Chichester, John Wiley, 1989, pp. 301-316.
30. Rubin RB, Barton AL, Banner BF: Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 13: 223-238, 1995.
31. Ikura Y, Morimoto H, Johmura H, et al: Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 91:1367-1373, 1996.
32. Bacon BR, Rebholz AE, Fried M, et al: Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-α. Hepatology 18:150A, 1993.
33. Hayashi I, Takikawa T, Nishimura N, et al: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89: 986-988, 1994.
34. Piperno A, Sampietro M, D'Alba R, et al: Iron stores, response to a-interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 16:248-254, 1996.
35. Van Thiel DH, Friedlander L, Molloy PJ, et al: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 43: 1557-1561, 1996.
36. Meyer B, Muller F, Luus H, et al: Faecal blood loss associated with aspirin and pentoxifylline, given alone and in combination. Drug Invest 4:215-218, 1992.
37. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of colon cancer. N Engl J Med 325:1593-1596, 1991.
38. Weinberg ED: Iron depletion: a defense against intracellular infection and neoplasia. Life Sci 50:1289-1297, 1992.
39. James SL: Role of nitric oxide in parasitic infections. Microbiol Rev 59:533-547, 1995.
40. Barbul A: Arginine: biochemistry, physiology, and therapeutic implications. Parent Enter Nutr 10:227-238, 1986.
41. Vincendeau P, Daulouede S, Veyret B, et al: Nitric oxidemediated cytostatic activity on Trypanosoma brucei gambiense and Trypanosoma brucei brucei. Exp Parasitol 75:353-360, 1992.
42. Karupiah G, Harris N: Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J Exp Med 181:2171-2179, 1995.
43. Clark IA, Rockett MA: Nitric oxide and parasitic disease. Adv Parasitol 37:5-36, 1996.
44. Weinberg ED: Acquisition of iron and other nutrients in vivo. In: Virulence Mechanisms of Bacterial Pathogens, edited by JA Roth, CA Bolin, KA Brogdon, et al, Washington, DC, Am Soc Microbiol, 1995, pp. 79-94.
45. Ala'aldeen DAA, Stevenson P, Griffiths E, et al: Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect Immun 62:2984-2990, 1994.
46. Holland J, Parsons TR, Hasan AA, et al: Conservation and antigenic cross-reactivity of the transferrin-binding proteins of Haemophilus influence, Actinobacillus pleuropneumoniae and Neisseria meningitidis. Microbiology 142:3505-3513, 1996.
47. Worst DJ, Sparrius M, Kuipers EJ, et al: Human serum antibody response against iron-repressible outer membrane proteins of Helicobacter pylori. FEMS Microbiol Lett 144:29-32, 1996.
48. Lundberg JH, Chitambar CR: Interaction of gallium nitrate with fluarabine and iron chelators: effects on the proliferation of human leukaemic HL60 cells. Cancer Res 50:6466-6470, 1990.
49. Kemp JD, Smith KM, Mayer JM, et al: Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells. Pathobiology 60:27-32, 1992.
50. Taetle R, Honeysett JM, Bergeron R: Combination iron depletion therapy. J Natl Cancer Inst 81:1229-1235, 1989.
51. Kemp JD: Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol Histopathol 12:291-296, 1997.
52. Hsieh-Ma S, Shi T, Reeder J, et al: In vitro tumor growth inhibition by bispecitic antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin Immunol Immunopathol 80:185-193, 1996.
53. Chitambar CR, Narasimhan J: Targetting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 59: 3-10, 1991.
54. Chitambar CR, Boon P, Wereley J: Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin Cancer Res 2:1009-1015, 1996.
55. Seligman PA, Schleicher RB, Siriwardana G, et al: Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood 82:1608-1617, 1993.
56. Dreicer R, Propert KJ, Roth BJ, et al: Vinblastine, ifosfamide, and gallium nitrate - an active new regimen in patients with advanced carcinoma of the urothelium. Cancer 79:110-114, 1997.
57. Byrd TF, Horwitz MA: Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 88:351-357, 1991.
58. Newman SL, Gootee L, Brunner G, et al: Chloroquine induces human macrophage killing of Hisloplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest 93:1422-1429, 1994.
59. Tsai W-P, Nara PL, Kung H-F, et al: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 6:481-489, 1990.
60. Sperber K, Kalb TH, Stecher VJ, et al: Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 9:91-98, 1993.
61. Sperber K, Louis M, Kraus T, et al: Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 17:622-625, 1995.